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Objectives: Chronic alveolar hypoxia induces pulmonary hypertension, evident from
elevated pulmonary artery pressure (PAP), pulmonary vascular resistance, right ventricular
hypertrophy (RVH), and increased muscularization of the pulmonary vasculature.
Additionally, the vasoconstrictor response to acute hypoxia (HPV) may be reduced in the
remodeled vasculature. However, no direct comparison of different treatments on the
various parameters characterizing pulmonary hypertension has been performed yet.
Against this background, we compared the effects of inhaled NO, infused iloprost, a stable
prostacyclin analogue, and oral sildenafil, a phosphodiesterase 5 inhibitor, on hypoxia-
induced pulmonary hypertension.
Methods: Exposure of rabbits to chronic hypoxia (FiO2 ¼ 0.10) for 42 days. Treatment with
infused iloprost, oral sildenafil, and inhaled nitric oxide.
Results: We quantified PAP, pulmonary vascular resistance, RVH, vascular remodeling,
vasoreactivity, and the strength of HPV. Chronic hypoxia resulted in an increase in (a) the
right ventricle/(left ventricle+septum) ratio from 0.2670.01 to 0.4470.01, (b) PAP, and
(c) the degree of muscularization from 14.074.0% to 43.575.3%. Treatment with iloprost
and sildenafil, but not with NO, prevented the increase in muscularization. In contrast,
RVH was strongly inhibited by sildenafil, whereas NO had some minor, and iloprost had no
effect. Only iloprost reduced PAP compared to NO and sildenafil. The downregulation of
HPV was abrogated only by NO.Published by Elsevier Ltd.
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N. Weissmann et al.2126Conclusion: We demonstrated (a) that the parameters characterizing hypoxia-induced
pulmonary hypertension are not functionally linked, (b) that the downregulation of HPV
under chronic hypoxia can be prevented by inhaled NO but not by sildenafil and iloprost,
and (c) that iloprost is particularly effective in preventing vascular remodeling and
sildenafil in preventing RVH.
& 2007 Published by Elsevier Ltd.Introduction
Hypoxia-induced pulmonary hypertension is characterized
by increased pulmonary vascular resistance, narrowing of
pulmonary vascular lumen due to thickening of the vessel
media, changes in functional parameters of the lung
vasculature, and right ventricular hypertrophy.1–3 In
contrast to these pathophysiological effects of chronic
alveolar hypoxia, acute alveolar hypoxia induces a
vasoconstrictor response that matches lung perfusion to
regional alveolar oxygen delivery, and thereby optimizes
pulmonary gas exchange. This process of hypoxic pulmonary
vasoconstriction (HPV), however, is also thought to
contribute to the development of pulmonary hyperten-
sion under conditions of generalized chronic hypoxia. In
this context, we recently demonstrated that acute HPV is
downregulated after chronic alveolar hypoxia and can
be restored by continuous treatment with inhaled nitric
oxide.4
Although the underlying mechanisms of hypoxia-
induced pulmonary hypertension have not been fully
elucidated, it has been shown that vasodilator therapies
can reduce the increase in pulmonary vascular resistance,
right ventricular hypertrophy, and the increase in the
degree of muscularization of the pulmonary vasculature
occurring during chronic hypoxia.5–11 However, it is not
determined yet, whether the increase in pulmonary
vascular resistance, the vascular remodeling process,
changes in the strength of HPV, and right ventricular
hypertrophy are functionally linked or differentially af-
fected by vasodilators. Therefore, we compared the effects
of inhaled NO, oral sildenafil, and intravenous iloprost on
these parameters in a rabbit model of hypoxia-induced
pulmonary hypertension. Interestingly, different efficacy
profiles were noted for the different vasoactive agents,
suggesting non-uniformity of action on key variables of
pulmonary hypertension.Materials and methods
Reagents
Krebs-Henseleit-buffer was from Serag-Wiessner (Naila,
Germany). U46619 was from Paesel+Lorei (Frankfurt/M,
Germany) and NG-monomethyl-L-arginine was from Sigma
(Deisenhofen, Germany). Sildenafil was from Pfizer (Sand-
wich, UK). Iloprost was from Schering (Berlin, Deutschland).
All other biochemicals were obtained from Merck (Munich,
Germany). Gases were from Messer-Griesheim (Siegen,
Germany).Chronic hypoxia
All animal experiments were approved by the local ethics
committee [Regierungspra¨sidium Giessen, numbers 17a-10c
20-15(1)-Gi 20/10-3/95 and 25.3-19c 20/15(1)-Gi20/10-20/99].
Rabbits (Chinchilla bastard) of either sex (2.5–3.2 kg) were
exposed to normobaric hypoxia [inspiratory O2 fraction
(FiO2) 0.10] in a ventilated chamber for 6 weeks. The level
of hypoxia was held constant by an autoregulatory control
unit (O2 controller model 4010, Labotect, Go¨ttingen,
Germany), supplying either nitrogen or oxygen. Excess
humidity in the recirculating system was prevented by
condensation in a cooling system. CO2 was continuously
removed by soda lime. Cages were opened once per day for
cleaning as well as food and water supply or refilling of the
infusor.Treatment with NO, iloprost and sildenafil
Animals were treated with inhaled NO, oral sildenafil or
intravenously infused iloprost (n ¼ 8 each). The normoxic as
well as the hypoxic control group consisted of n ¼ 12
animals each. After 42 days of normoxia or hypoxia, the
animals were subjected to the following protocol: quanti-
fication of right ventricular pressure in anesthesia (ketamin/
xylazine), isolated lung perfusion, and subsequent fixation
for histological investigation as well as determination of
right ventricular hypertrophy. Due to technical reasons,
perfusion as well as the histological investigation was
performed for only n ¼ 5 lungs in the iloprost treated
animals. Animals were randomly allocated to the different
groups.
For treatment with inhaled NO, this agent was continu-
ously flushed into the animal cages to achieve a concentra-
tion of 15 ppm. The NO concentration was controlled twice
daily by an NO analyzer (Sievers 280 NOA, Sievers Instru-
ments, Boulder, CO, USA). The dosage applied was selected
from effective therapeutic and pulmonary vasodilatory
dosages previously determined in rabbits in our laboratory
as well as in humans. These dosages ranged approximately
10–200 ppm.12–14 To avoid significant NO2 formation (which
was continuously controlled in the hypoxic cages by a Dra¨ger
Multiwarn II [Dra¨ger, Lu¨beck, Germany]) and protein nitra-
tion12 the highest tolerable dosage with regard to NO
insufflation into the hypoxia cages was determined at
15 ppm which was then used for treatment in the present
study.
For treatment with sildenafil, this agent was added to the
drinking water. Rabbits received 4.3mg/kg body weight/
day. The dosage was selected upon our previous finding
and as high as possible without significant systemic
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period of 1 week before onset of treatment to calculate the
uptake of water per day. The concentration of sildenafil in
the drinking water was then adjusted accordingly. During
the 6-week period of treatment, no significant alterations in
the daily water consumption were observed.
For treatment with iloprost, this agent was infused
continuously via a Hickman catheter into the left jugular
vein in a dose of 15 ng/kg body weight/min by an infusion
pump (Multidayinfusor 0.5ml/h, Baxter, Lessins, Belgium).
The dosage was determined in previous investigations from
our laboratory to result in significant pulmonary vascular
vasodilation without a decrease in systemic vascular
resistance.16 The infusion catheter was tunneled through
the neck and connected to the infusor on the back of the
animal. Implantation of the catheter was performed under
anesthesia by intravenous application of ketamine
(15–25mg/kg body weight) and xylazine (3–5mg/kg body
weight) 7 days before onset of treatment of the animals.
Until onset of treatment, all animals received 0.2ml/kg
body weight/day Baytril 10% (Bayer, Leverkusen, Germany)
and 250U heparin/kg body weight/day. The animals of the
hypoxic and normoxic control group received a continuous
infusion of saline.
Treatment was started in parallel with the onset of
hypoxia. Rabbits exposed to normobaric normoxia were kept
in a similar chamber as the hypoxic animals but at an FiO2
of 0.21.
After 42 days of exposure to either chronic hypoxia or
normoxia, right ventricular pressure was measured by means
of a pulmonary arterial catheter in ventilated (30 strokes/
min, tidal volume 30ml, room air) and anaesthetized
animals [combined intravenous application of ketamine
(30–50mg/kg body weight) and xylazine (6–10mg/kg body
weight); anticoagulaion was achieved by intravenous appli-
cation of heparin (1000U/kg body weight)]. For mechanical
ventilation, an endotracheal tube was introduced into the
trachea and the animals were ventilated with room air. After
measurement of pulmonary artery pressure, lungs were
investigated in an isolated lung preparation and hearts
were removed to calculate right ventricular wall (RV) to
left ventricular wall (LV) plus septum ratio of the dried
heart tissue.Lung isolation, perfusion and ventilation
The model of isolated perfused rabbit lungs has been
described previously.4,17 Briefly, rabbits were deeply anaes-
thetized as stated above and ventilated with room air. The
lungs were excised while being perfused with Krebs
Henseleit buffer through cannulas in the pulmonary artery
and the left atrium. The buffer contained 125.0mM NaCl,
4.3mM KCl, 1.1mM KH2PO4, 2.4mM CaCl2, 1.3mM MgCl2 and
275mg glucose per 100ml; NaHCO3 was adjusted to result in
a constant pH range of 7.37–7.40. After rinsing the lungs
with at least 1 l of buffer fluid for washout of blood, the
perfusion circuit was closed for recirculation (total system
volume 250ml). Meanwhile, the flow was slowly increased
from 20 to 150ml/min, and left atrial pressure was set at
1.5–2.0mmHg to ensure zone III conditions throughout the
lung at end expiration. The alternate use of two separateperfusion circuits allowed repeated exchange of buffer
fluid. In parallel with the onset of artificial perfusion,
ventilation was changed from room air to a mixture of 5.3%
CO2, 21.0% O2, balanced by N2 (tidal volume, 30ml;
frequency, 30 strokes/min). A positive end-expiratory pres-
sure (PEEP) of 1 cm H2O was chosen (0 referenced at the
hilum). The isolated perfused lungs were placed in a
temperature-equilibrated housing chamber, freely sus-
pended from a force transducer for continuous monitoring
of organ weight. The whole system (perfusate reservoirs,
tubing, housing chamber) was heated to 38.5 1C. Pressures in
the pulmonary artery, the left atrium and the trachea were
registered by means of small-diameter tubing threaded into
the perfusion catheters and the trachea and connected to
pressure transducers. Lungs included in the study were
those that (i) had a homogeneous white appearance with no
signs of hemostasis, edema or atelectasis, (ii) revealed
constant mean pulmonary artery and peak ventilation
pressure in the normal range, and (iii) were isogravimetric
during the initial steady state period of at least 20min.
Weight increase ranged o3 g throughout the entire
experiments.
Hypoxic maneuvers and pharmacological challenges
The technique of successive hypoxic maneuvers in buffer-
perfused rabbit lungs has been described previously.18,19
Briefly, a gas-mixing chamber (KM 60-3/6MESO, WITT,
Witten, Germany) was employed for step-changes in the
ventilator O2 content [21% (v/v) (alveolar PO2 160mmHg,
baseline conditions) to 3% (v/v) (alveolar PO2 23mmHg,
hypoxic conditions)]. 5.3% (v/v) CO2 was used throughout,
and the percentage of N2 was balanced accordingly. Two
hypoxic maneuvers of 10-min duration, interrupted by a 15-
min period of normoxia, were performed. Fifteen minutes
after cessation of hypoxia two bolus applications of the
stable thromboxane mimetic U46619 (addition at an interval
of 15min to the perfusate at 0.5 nM) were undertaken for
investigating lung vascular reactivity to this agent as
described previously.19,20 The sequence of hypoxic and
U46619 challenges was started 80–100min after removal
of the animals from the hypoxic chambers. For analysis, the
maximum strength of the second hypoxic challenge and the
first U46619 challenge was quantified. Normoxic vascular
tone was assessed after the initial steady state period.
Measurement of exhaled NO
The technique for monitoring of exhaled NO of isolated
rabbit lungs has been described previously.21 Briefly, an
aliquot of the mixed expired gas was continuously forwarded
to a chemiluminescence NO-analyzer (Sievers 280 NOA,
Sievers Instruments, Boulder, CO, USA), and its NO quantity
measured in ppb (parts per billion, v/v).
Vessel morphometry
For histological analysis, the isolated lungs were perfused
with Zamboni’s fixative for 30min at a pulmonary artery
pressure of 15mmHg and a left ventricular pressure of
2mmHg. After ligation of the pulmonary artery and veins
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Figure 1 Right heart hypertrophy. Ratio of right ventricular
wall (RV) to left ventricular wall plus septum (LV+septum). Data
are given for hearts of normoxic control animals (normoxia) and
animals after 42 days of chronic normobaric hypoxia (10% O2)
from at least five animals per group. ***Significant difference
compared to normoxic control (po0.001). #Significant differ-
ence (po0.05) compared to 42 days of hypoxia, receiving
saline. (ypo0.05, yyypo0.001) Significant difference between
the different treatment groups.
N. Weissmann et al.2128lungs were removed and placed in the Zamboni fixative for
6 h at room temperature. After incubation for 12 h at 4 1C in
0.1M phosphate buffer, the tissue was dehydrated and
infiltrated with paraffin wax in an automated vacuum tissue
processor (Leica TP1050, Bensheim, Germany). Sections
(3 mm) were stained with anti-a-smooth muscle actin anti-
body (dilution 1:900, clone 1A4, Sigma, St. Louis, MO)
pretreated with trypsin (10min, 37 1C). For detection, the
Vectastain ABC Elite Kit Mouse IgG (Vector/Linaris,
Wertheim-Bettingen, Germany) was used according to the
manufacturer’s protocol. For visualization, the Vector VIP
substrate kit for peroxidase (Vector/Linaris, Wertheim-
Bettingen, Germany) was applied. Nuclear counterstaining
was done with methyl green (Vector/Linaris, Wertheim-
Bettingen, Germany). For determination of the degree of
muscularization, vessels with a diameter ranging 80–150 mm
were classified as non-muscular (no smooth muscle cells
detectable with actin staining), partially muscularized (at
least one smooth muscle cell up to 75% circumference with
actin staining), and fully muscularized (X75% of circumfer-
ence with actin staining) as described previously.22
The analysis was done in the left upper, right lower and
left lower lobe by counting 50 vessels from each lobe.
The portion of the vessels from each category was
calculated in percent of total vessel count. The morpho-
metric analysis was done from sections blinded for the
investigator.
Statistics
For calculation of statistical differences, analysis of
variance with the Student–Newman–Keuls post hoc test
was performed for comparison of more than two groups.
For analysis of two groups, a Student’s t-test was applied.
Statistical significance was assumed when p ranged
o0.05. Data are given as mean7standard error of the
mean (SEM).
Results
Exposure of the animals to chronic normobaric hypoxia (10%
O2) for a period of 42 days resulted in a significant increase
in the ratio of RV/(LV+septum) (Figure 1). In contrast to
iloprost, treatment with NO significantly reduced the
increase in right ventricular hypertrophy. The preventive
effect of sildenafil was even more pronounced (Figure 1). A
different profile was evident for pulmonary artery pressure
measured in the intact animal as well as in the isolated lung
preparation (Figure 2). When PAP was assessed in the intact
animal only iloprost reduced PAP when compared to NO and
sildenafil (Figure 2a). In isolated, blood-free, perfused lungs
of these animals, no significant difference was detected
between the groups treated with iloprost, NO, or sildenafil:
all treatments only showed a tendency towards minor
reduction of PAP under these conditions of in vitro perfusion
(Figure 2b). The degree of muscularization of the pulmonary
vasculature was significantly increased after chronic hypox-
ia. The portion of fully muscularized vessels was increased
from 14.074.0% to 43.575.3% (n ¼ 12). In parallel, the
portion of the non-muscularized vessels decreased from
39.674.8% to 12.472.9%. The increase in the portion of thefully muscularized vessels was equally prevented in the
iloprost and the sildenafil treated groups, but not in the NO
treated group (Figure 3). The decrease in the portion of the
non-muscularized vessels occurring during chronic hypoxia
was not significantly affected by any of the treatment
regimes. Iloprost increased the portion of partially muscu-
larized vessels as compared to the hypoxic and normoxic
control (Figure 3).
When explanted perfused and ventilated lungs were
challenged with acute hypoxic ventilation maneuvers, a
significant reduction in the strength of HPV from 2.270.4 to
0.970.1mmHg (n ¼ 12) was observed, as described pre-
viously.4 This decrease was virtually abrogated in the NO
treated group, but not in the sildenafil- and iloprost-treated
groups (Figure 4a). As previously described, chronic hypoxia
downregulated HPV but not vasoconstrictions induced by the
thromboxane mimetic U46619, excluding a general effect of
chronic hypoxia on vascular contractility (Figure 4b).4 Only
treatment with NO showed a tendency towards an increased
response to vasoconstrictor challenges with U46619
(Figure 4b).
Exhaled NO levels in the isolated perfused lung prepara-
tion were 10979 ppb and were not affected by exposure to
chronic hypoxia (11677 ppb) or any of the treatment
regimes. During acute hypoxic ventilation, a sudden
decrease by 2372 ppb (n ¼ 5–12 each) in exhaled NO levels
occurred, persisting the entire hypoxic ventilation period
as previously described.23 This decrease was also not
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Figure 2 Pulmonary artery pressure assessed in vivo and in the
isolated perfused and ventilated lung preparation. Pulmonary
artery pressure was either assessed in the anesthetized animal
(a) or in the ex vivo perfused and ventilated lung (b). Data are
given for normoxic controls (normoxia), animals exposed to
chronic hypoxia only, and chronic hypoxic animals treated with
iloprost, NO, or sildenafil. Data from the isolated lung
preparation are taken after the initial steady state period of
lung perfusion. Data are from at least n ¼ 5 animals per group.
*po0.05, **po0.01, and ***po0.001 indicate significant differ-
ences compared to normoxic controls. #po0.05 indicates
significant differences compared to hypoxic controls.
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Figure 3 Degree of muscularization in small pulmonary vessel.
(a) The portion of fully muscularized, partially muscularized,
and non-muscularized vessels (80–150 mm in diameter) is given
in percent of total vessel count. *po0.05, **po0.01, and
***po0.001 indicate significant differences compared to nor-
moxic controls. #po0.05 indicates significant differences
compared to hypoxic controls. (b) Representative examples
for immunostaining against a-smooth muscle actin in non (non),
partially (partial), and fully (full) muscularized vessels.
Treatment of hypoxia-induced pulmonary hypertension 2129significantly affected by chronic hypoxia exposure
(2272 ppb, n ¼ 12) exposure or any of the treatments.Discussion
The present study explored the effects of inhaled NO,
intravenous iloprost and oral sildenafil on right ventricularhypertrophy, pulmonary hemodynamics, structural changes
of the pulmonary vasculature, and acute HPV in a rabbit
model of hypoxia-induced pulmonary hypertension. Expo-
sure of rabbits to 42 days of chronic hypoxia resulted in
development of pulmonary hypertension with a significant
increase in pulmonary artery pressure and pulmonary
vascular resistance, right ventricular hypertrophy and an
increased muscularization of distal pulmonary vessels.
These effects are comparable to those found in other
species such as mice and rats8,24 and are accordance with
our recent investigation in this rabbit model.4General hemodynamic effects and structural
changes of the pulmonary vasculature
When comparing the effects in the different groups treated
with inhaled NO, intravenous iloprost or oral sildenafil,
sildenafil was the most effective agent in the prevention of
right ventricular hypertrophy. However, this effect did not
correlate with the effect of sildenafil on pulmonary artery
pressure assessed in vivo. Elevation of PAP under chronic
hypoxia was prevented in all of the treatment groups with
ARTICLE IN PRESS
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Figure 4 Strength of vasoconstrictor response to acute
hypoxic challenge (a) or U46619 bolus application (b). Maximum
vasoconstrictor response to (a) an acute hypoxic ventilation
maneuver (3% O2, 10min) or to (b) the bolus application of
U46619, resulting in a concentration of 0.5 nM in the recirculat-
ing buffer fluid. Data are given for normoxic controls and lungs
from animals exposed to 42 days of chronic hypoxia (10% O2) and
the indicated treatment groups. **po0.01 and ***po0.001
indicate significant differences compared to normoxic control.
#po0.05 indicates significant differences compared to hypoxic
control. +Significant difference (po0.05) of the strength of HPV
compared to the strength of the U46619-induced vasoconstric-
tor response. ySignificant difference (po0.05) between the
different treatment groups.
N. Weissmann et al.2130the most prominent effect observed for iloprost. A quite
similar pattern was found when lungs were investigated
in the isolated perfused lung preparation, where PAP
directly reflects pulmonary vascular resistance. Under these
conditions, the increase in pulmonary vascular resistance
was less significant in all treatment groups with no
differences between the different treatment regimes. Theslight differences between the PAP measurements in vivo
and in the isolated lung may be explained by (1) the fact
that pulmonary artery pressure determined in the isolated
lung is generally lower than in vivo, making it more difficult
to discriminate changes with statistical significance and (2)
by the fact that changes in cardiac output may affect PAP in
vivo. Quantification of the degree of vascular musculariza-
tion revealed that not even this structural parameter
indicative of pulmonary hypertension correlated with the
effects of sildenafil, NO, and iloprost on right ventricular
hypertrophy, PAP, or pulmonary vascular resistance. The
increase in the degree of muscularization was prevented by
sildenafil and iloprost, but not by NO; whereas sildenafil was
the most effective agent in reducing right ventricular
hypertrophy, and iloprost was the most effective agent in
reducing PAP. These findings favorably support the idea that
different mechanisms underlie the hemodynamic effects of
the different treatment regimes, and that the vascular and
right ventricular remodeling processes occurring in chronic
hypoxia are not necessarily correlated with each other, or
with the changes observed in hemodynamics. Such a view
challenges previous observations, demonstrating that in-
creases in pulmonary artery pressure correlate well with the
development of right ventricular hypertrophy (e.g. 25,26).
Although there is no doubt that an increase in pulmonary
vascular resistance induces right ventricular hypertrophy,
there is good reason to assume that right heart hypertrophy
can be suppressed without a preceding reduction in
pulmonary vascular resistance. In this regard, Takimoto
et al.27 have shown that left heart hypertrophy can be
reduced in a model of arterial banding. Such differential
effects may be caused by different proproliferative mechan-
isms being active in right heart and vascular remodeling,
which, in addition, may differentially be affected by the
agents used for treatment in our study. In addition, our data
suggest that hypoxia per se can induce right heart
hypertrophy as both the degree of muscularization as well
as the pulmonary vascular resistance was lowered by
iloprost without significant reduction in right heart hyper-
trophy. Moreover, it has been questioned whether an
increase in the degree of muscularization is sufficient per
se to increase pulmonary vascular resistance.28 Thus,
together with our study, there is good evidence that indeed
such suggestions are valid for pulmonary hypertension. Even
if our data cannot exclude that different dosages of the
respective agents applied could have different effects on
the different parameters of pulmonary hypertension, our
data at least prove that the various parameters can be
affected separately and that not all of them are necessarily
linked. Future studies with a curative approach may resolve
if this is also true for reversal of pulmonary hypertension,
when starting the treatment after establishment of hypoxia-
induced pulmonary hypertension.
Comparing our data to previous studies, investigations in
mice and rats revealed that treatment with oral sildenafil
reduces the hypoxia-induced increase in right ventricular
mass, pulmonary artery pressure and muscularization of
small pulmonary arterial vessels.8,9,11 These findings are
well in line with our observations.
For inhaled NO, a reduction in right ventricular hyper-
trophy and de novo muscularization induced by chronic
hypoxia was reported.6,7 The failure of inhaled NO to
ARTICLE IN PRESS
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isolated lung preparation is in line with the investigation
of Frank et al.29 in rats. In contrast to the investigations in
rats,6,7 the vascular remodeling process induced by chronic
hypoxic exposure was not attenuated by inhaled NO in our
experiments, although Kouyoumdjan et al.6 also used a
concentration of NO as low as in our investigation. These
differences may reflect species variations as to the role of
NO in the vascular remodeling process.
Concerning the effects of iloprost, to the best of our
knowledge, only one recent investigation exists, appearing
while the manuscript for the present investigation was in
preparation, which investigated the effects of this agent on
the hypoxia-induced vascular remodeling processes and
pulmonary hemodynamics.10 However, no significant effect
was observed in this investigation in rats, although a 10-fold
higher iloprost concentration was applied compared to our
investigation, which again may reflect species differences.
Studying the effect of iloprost on vascular remodeling is
clearly important, since it has been shown that long-term
therapy with iloprost improves exercise tolerance in
patients with severe pulmonary arterial hypertension.30
This is in line with the effects of prostacyclin, shown to
antagonize the development of hypoxia-induced pulmonary
hypertension in mice chronically overexpressing PGI2
synthase.5 Although iloprost is used as an aerosol for
treatment of patients with pulmonary hypertension, we
applied this agent intravenously to assure constant dosing.
However, comparing the effectiveness of our study with the
effect of inhaled iloprost in monocrotaline-induced pulmon-
ary hypertension in rats suggests a similar effective dosage
to be active in our investigation.31Effects on hypoxic pulmonary vasoconstriction
In addition to the basal hemodynamic changes, we assessed
the vasoreactivity to acute hypoxic and pharmacological
vasoconstrictor challenges. In this context, we have recently
demonstrated that hypoxic vasoconstriction, but not vaso-
constrictions induced by the thromboxane mimetic U46619,
are downregulated in rabbits after exposure to chronic
hypoxia,4 and that HPV is restored by chronic treatment
with inhaled NO, which is suggested to be an unspecific
effect resulting in amplified vasoreactivity.4 Beyond these
investigations, we have now additionally investigated the
effects of sildenafil and iloprost on the downregulation of
HPV. Interestingly, only in the NO-treated group was the
downregulation of HPV prevented, whereas treatment solely
with sildenafil or with iloprost did not affect the attenuation
of HPV. The lack of an effect of sildenafil suggests that the
preservation of HPV by NO is probably not facilitated by
stimulation of cGMP synthesis. Moreover, we have now
demonstrated for the first time that stimulation of the cAMP
axis by iloprost does not restore HPV after chronic hypoxia,
again supporting the idea that the preservation of HPV by NO
is independent of cyclic nucleotides. Finally, our data
suggest that the prevention of the downregulation of HPV
by NO is not related to changes in lung NO synthesis, as no
change in exhaled NO occurred in the different treatment
groups (exhaled NO has been proven to be a good indicatorfor vascular NO production in isolated blood-free perfused
lungs).4,21
In conclusion, we demonstrated (a) that the parameters
characterizing development of hypoxia-induced pulmonary
hypertension, namely pulmonary artery pressure, pulmonary
vascular resistance, right ventricular hypertrophy, vascular
remodeling, and changes in vasoreactivity, are not function-
ally linked in rabbits under chronic hypoxia, (b) that the
downregulation of HPV occurring under conditions of chronic
alveolar hypoxia can be prevented by inhaled NO but not by
sildenafil and iloprost, which suggests that restoration of
HPV by NO is unrelated to the second messengers of NO,
cGMP, and (c) that iloprost treatment is particularly
effective in preventing lung vascular remodeling and
sildenafil in preventing right heart hypertrophy in hypoxic
induced pulmonary hypertension in rabbits.
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